

## FY2020 H1 Earnings Ended September 30, 2020



Oct. 29, 2020 OMRON Corporation

#### **Summary**

#### ■ H1 FY2020 Results

- Sales, operating profit exceed Q1 forecasts despite tough environment
- GP margin continues to improve. Fixed cost discipline in line with plan.
   Excluding forex impact, profits up Y/Y
- Both IAB and HCB outperform expectations: IAB by capturing Digital demand in China and South Korea, HCB by successfully capturing COVID-19 demand

#### ■ Full-year Forecasts

- Revising up full-year sales and OP forecasts based on H1 results
- Expect overall H2 outlook to remain tough; prospects by region/industry mixed
- Fully committed to executing fixed cost cut plan; additional growth investments to be undertaken selectively

#### **■ HCB Growth Strategy: Preparing for Post-COVID-19**

- Expanding BPM, Remote Medical Service initiatives to achieve Zero Events
- Progress on regional expansion of Remote Medical Service through partnerships

#### **Contents**

1. H1 FY2020 F	lesults
----------------	---------

P. 3

2. FY2020 Forecasts


P. 11

3. HCB Growth Strategy

P. 19

Reference

P. 29



## **H1 Results**

#### **H1 Results**

Exceed Q1 forecasts despite tough environment. Profits up if forex impact excluded. GP margin continues to improve


	H1 FY2019 Actual	H1 FY2020 Actual	Y/Y	
	Actual	Actual		
Net Sales	330.2	301.3	-8.8%	
Gross Profit	148.8	136.4	-8.3%	
(%)	(45.0%)	(45.3%)	(+0.2%pt)	Excluding
Operating Income	25.7	24.7	-3.9% <	forex impact +7.6%
(%)	(7.8%)	(8.2%)	(+0.4%pt)	
Net Income	22.4*	19.2	-14.5%	
1USD (JPY)	109.2	106.9	-2.3	
1EUR (JPY)	122.0	120.9	-1.1	
1RMB (JPY)	15.9	15.2	-0.7	

<sup>\*</sup>H1 FY2019 Net Income excludes Quarterly Net Loss from Discontinued Operations. If Quarterly Net Loss from Discontinued Operations is included, Net Income would be ¥19.1bn

pact

#### **Operating Income Analysis (Y/Y)**

#### Fixed cost discipline maintained in line with plan



H1 FY2019 Actual

\*Includes impact of yen appreciation

H1 FY2020 Result

#### **Sales by Business Segment**

#### **HCB** sales up on higher BPM and thermometer sales

(¥bn)

	H1 FY2019 Actual	H1 FY2020 Actual	Y/Y
IAB Industrial Automation	177.9	164.9	-7.3%
EMC Electronic & Mechanical Components	45.9	38.8	-15.4%
SSB Social Systems, Solutions & Service	46.4	37.4	-19.4%
HCB Healthcare	54.6	57.5	+5.3%
Eliminations & Corporate	5.4	2.6	-51.3%
Total	330.2	301.3	-8.8%

<sup>\*</sup>FY2019 figures adjusted to reflect the transfer of the Environmental Solutions business from the Other segment to SSB and the winding down of the Backlight business.

#### **IAB Sales Growth by Region**

Greater China and South Korea sales up on continued success in capturing Digital demand

# H1 FY2020 IAB Sales Growth by Region

(Y/Y, local currency basis)

Japan	Americas	Europe	Greater China	SE Asia	/Other
Japan	Americas	Larope		Ex-S. Korea	S. Korea
-12%	-12%	-15%	+19%	-15%	+17%

#### IAB: Initiatives During the COVID-19 Outbreak

Successfully captured capex growth opportunities on a global basis, in spite of the COVID-19 outbreak

### **Demand Related to COVID-19 Measures**





Mask

**Manufacturing Line** 





Ventilator

UV-C
Irradiation Robot

**AXI** 

(X-ray Substrate Inspection Equipment)



Captured opportunities on global basis

H1 sales ¥4.0 bn

Captured automotive and 5G base station demand

H1 sales +40% Y/Y

#### **HCB: Responding to Rising Demand for Thermometers**

Rapid capacity expansion drove strong sales growth.

Preparations for further demand increases already in place



#### **Dalian Plant, China**



Large-scale capacity expansion

#### Matsusaka Plant, Japan



Production started in October

(\text{\tin}}\text{\tin}\text{\te}\tint{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\texi}\text{\text{\text{\text{\text{\texi}\tint{\text{\texi}}\tinttitex{\text{\texi}\tint{\text{\text{\text{\text{\texi}}\xi}\tex

#### **Operating Income by Business Segment**

#### **HCB** profits up significantly

	(13.17 78.8.17)				
	H1 FY2019	H1 FY2020	Y/Y		
	Actual	Actual	1/1	Y/Y	
IAB	27.6	26.4	-1.2	+¥0.8bn (Local currency	
Industrial Automation	(15.5%)	(16.0%)	(+0.5%pt)	basis)	
EMC	0.7	0.3	-0.3		
Electronic & Mechanical Components	(1.5%)	(0.8%)	(-0.6%pt)		
SSB	1.9	-1.2	-3.0		
Social Systems, Solutions & Service	(4.0%)	(-)	(-)	Y/Y	
НСВ	6.9	10.6	+3.7	+54%	
Healthcare	(12.6%)	(18.5%)	(+5.8%pt)		
Eliminations & Corporate	-11.3	-11.4	-0.1		
Total	25.7	24.7	-1.0		
TOtal	(7.8%)	(8.2%)	(+0.4%pt)		

<sup>\*</sup>FY2019 figures adjusted to reflect the transfer of the Environmental Solutions business from the Other segment to SSB and the winding down of the Backlight business



# Full-year Forecasts

#### **H2 Business Environment by Segment**

#### Tough overall operating environment but outlook mixed depending upon region and industry

IAB

**Industrial Automation** 

Automotive: Auto sales down on COVID-19; expect capex to remain weak

Investments paused primarily in China and S. Korea but underlying trend firm Digital:

Food & bev.: Continued macro impact but COVID-19-related demand supportive. Gradually recovering Social infrastructure: Flat Y/Y overall on government stimulus measures despite COVID-19 impact

**EMC** 

**Electronic & Mechanical** Components

Consumer:

Recovery continues in Americas and China, where recovery relatively early. Expect gradual

recovery in Europe and Asia

Automotive: Auto sales improving on global basis but weak trend likely to continue on full-year basis

**SSB** 

Social Systems, **Solutions & Service**  Station sys.:

Capex appetite increasingly in decline; demand to be weak

Transport:

Expect firm replacement demand to continue

Energy:

Restart of sales activity to support gradual recovery in sales of battery storage systems

**HCB** 

Healthcare

Firm, primarily in thermometers. Expect gradual recovery in store sales on reopening Domestic:

Overseas:

Online sales firm primarily in BPMs. Similar to domestic store sales, expect gradual recovery

(Yhn)

#### **FY2020 Forecast**

#### Revised full-year forecasts. Expect GP margin to improve Y/Y


	_				(¥bn)
	FY2020	FY2020	Chg. Vs Plan	FY2019	Y/Y
	Previous Plan	Forecast	J	Actual	- , -
Net Sales	590.0	620.0	+5.1%	678.0	-8.6%
Gross Profit	264.5	279.5	+5.7%	303.7	-8.0%
(%)	(44.8%)	(45.1%)	(+0.3%pt)	(44.8%)	(+0.3%pt)
Operating Income	30.0	40.0	+33.3%	54.8	-27.0%
(%)	(5.1%)	(6.5%)	(+1.4%pt)	(8.1%)	(-1.6%pt)
Net Income	16.5	24.0	+45.5%	39.2	-38.8%
1USD (JPY)	106.5	105.9	-0.6	109.1	-3.2
1EUR (JPY)	119.6	122.5	+2.9	121.2	+1.3
1RMB (JPY)	15.0	15.2	+0.2	15.7	-0.5

<sup>\*</sup> FY2019 Net Income excludes Net Income from Discontinued Operations.

If Net Income from Discontinued Operations is included FY2019 Net Income would be ¥74.9bn

#### **Operating Income Analysis (Y/Y)**

# Committed to executing on fixed cost reduction plan but will also selectively undertake additional growth investments



\*Includes impact of yen appreciation

Actual

**Forecast** 

#### **Sales by Business Segment**

#### Sales forecasts for IAB, EMC and HCB revised up


(¥bn)

	FY2020	FY2020	Chg. Vs Plan	FY2019	Y/Y	
	Previous Plan	Forecast	Crigi VS Flair	Actual	., .	
IAB Industrial Automation	307.0	322.0	+4.9%	352.8	-8.7%	
EMC Electronic & Mechanical Components	76.0	81.0	+6.6%	88.4	-8.3%	
SSB Social Systems, Solutions & Service	93.0	93.0	±0.0%	116.0	-19.8%	
HCB Healthcare	112.0	119.0	+6.3%	112.0	+6.3%	
Eliminations & Corporate	2.0	5.0	-	8.9	-43.5%	
Total	590.0	620.0	+5.1%	678.0	-8.6%	

<sup>\*</sup>FY2019 figures adjusted to reflect the transfer of the Environmental Solutions business from the Other segment to SSB and the winding down of the Backlight business

#### **IAB: Expected Quarterly Sales Trend by Region**

Q2 sales for Greater China and S. Korea exceeded plan. Now expect sales for Greater China to be up Y/Y throughout the year



#### **Operating Income by Business Segment**

#### Upward revisions primarily focused on IAB, HCB

(\text{\tin}}\text{\tin}\text{\te}\tint{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\texi}\tin}\text{\text{\text{\texi}}\\tinttitex{\text{\text{\text{\text{\text{\texi}}\xi}\tex

	FY2020 Previous Plan	FY2020 Forecast	Chg. Vs Plan	FY2019 Actual	Y/Y
IAB	35.0	44.0	+9.0	53.6	-9.6
Industrial Automation	(11.4%)	(13.7%)	(+2.3%pt)	(15.2%)	(-1.5%pt)
EMC	0.5	1.0	+0.5	0.9	+0.1
Electronic & Mechanical Components	(0.7%)	(1.2%)	(+0.6%pt)	(1.0%)	(+0.2%pt)
SSB	5.0	5.0	±0.0	10.9	-5.9
Social Systems, Solutions & Service	(5.4%)	(5.4%)	( - )	(9.4%)	(-4.0%pt)
НСВ	15.0	17.0	+2.0	13.5	+3.5
Healthcare	(13.4%)	(14.3%)	(+0.9%pt)	(12.1%)	(+2.2%pt)
Eliminations & Corporate	-25.5	-27.0	-1.5	-24.1	-2.9
Total	30.0	40.0	+10.0	54.8	-14.8
ı utal	(5.1%)	(6.5%)	(+1.4%pt)	(8.1%)	(-1.6%pt)

<sup>\*</sup>FY2019 figures adjusted to reflect the transfer of the Environmental Solutions business from the Other segment to SSB and the winding down of the Backlight business

#### **Annual Dividend**

H1 dividend fixed at ¥42. Maintain full-year DPS guidance at ¥84. Fiscal year-end dividend guidance at ¥42

H1 DPS FY-end DPS Full-year DPS Fixed (Forecast) (Forecast)

FY2020 Forecast

¥42

¥42


¥84

FY2019 (Actual)

¥42

¥42

¥84



# HCB Growth Strategy for Post-COVID-19

#### **Going For Zero Events**



OMRON Healthcare is Going for Zero.

We aim to eliminate cerebral and cardiac events, such as stroke or heart attacks, that can lead to fatalities or being bedridden.

#### **Growing BPM Business in Emerging Markets (Brazil)**

Started BPM production in Brazil, where import tariffs are high, before peers. Ramping up additional capacity at new plant

#### **BPM Market Share in Brazil**

approx. **50%** 

\* Volume basis



#### **New Brazil Plant**








#### Growing BPM Business in Emerging Markets (India)

Market growth on recognition of importance of home monitoring.

Aiming for further sales growth leveraging on 2021 Drugs Act Revision



#### **Rising BPM Penetration**


Enhancing educational activities for Hypertension Society of India (OMRON Academy)

**Growth in online channel** 

Initiatives related to Drugs and Cosmetics Act

#### **Remote Medical Service Business Model**

#### **Developed Remote Medical Service business model**



#### **Global Expansion of Remote Medical Service**

Remote Medical Service aimed at Zero Events expanding beyond the US to the Netherlands, UK, India and Singapore

#### Netherlands/UK

More hospitals adopting remote medical service for specialists with Luscii Healthtech

#### **India**

Collaboration with Terrals
Technologies to ramp up
remote medical service

#### US

- LF # 13 ...

More hospitals adopting
Remote Patient
Monitoring (RPM)

#### **Singapore**

Ramping up remote medical and enhanced corporate wellness services with HeartVoice Pte.

#### Remote Medical Service: The Netherlands/UK

Remote medical services increasingly covered by insurance. Luscii making solid progress in expanding remote monitoring service

#### **Outlook: Insurance Coverage**

Europe: Coverage of online treatment and remote monitoring expected

to accelerate

UK: Penetration of remote treatment to accelerate on expected

changes to insurance system

#### Partner: Luscii Healthtech B.V.

**Based** The Netherlands

Est. November 2018

**Sales** 1.4M EUR (FY2019)

#### **Key service features**

•Enables remote monitoring of high-risk patients for cardiovascular specialists

#### Remote Medical Service: Singapore

Government support for remote medical services to further boost penetration. Accelerating OMRON's growth through HeartVoice

#### **Government, Corporate Initiatives in Remote Medicine**

Government: Providing support to medical institutions which adopt remote medical services from 2020

Corporates: Proactively invest in preventative medicine for employees (subsidizing employee wellness

management and periodic medical checkup fees)

#### Partner: iAPPS Pte.

**Based** Singapore

**Est.** August 2012

**Sales** 2.1M SGD (FY2019)

#### Rationale for partnership

- Strong relationship with Singaporean government
- Technology and know-how developed by providing wellness management to 1.6 million people

#### Joint Venture: HeartVoice Pte.

**Based** Singapore

**Est.** January 2019

**Sales** 6.6M SGD (FY2019)

#### **Key service features**

- Linked to employee wellness management service
- Remote medical service for patients with chronic conditions

#### **Global Development of Revolutionary Devices**

#### Going for Zero: Global deployment of revolutionary devices



**FY22 Plans** Up to FY19 **FY20 Plans FY21 Plans FY19 US** 2Q S. America 1Q Brazil 4Q Europe 2Q Asia 4Q China -4Q Japan



**FY15 US** 

3Q Europe-

4Q Brazil

1Q China 1Q Japan

\*Selling AlivCor products from FY19




**4Q US** FY18 US (Next-gen model)

FY19 Europe -

FY19 Japan -


# OMRON




## Reference

#### **Segment Changes**

Eliminating Other segment: Environmental Solutions business transferred to SSB, winding down Backlight business





#### **Consolidated Balance Sheet**

(¥bn)

	End-March 2020	End-Sept 2020	Y/Y
Current assets	447.1	444.5	-2.7
(Cash and cash equivalents)	(185.5)	(209.1)	(+23.6)
(Inventory)	(104.3)	(109.6)	(+5.3)
Property, plant and equipment	114.5	111.5	-3.0
Investments and other assets	196.5	196.4	-0.1
Total assets	758.1	752.4	-5.8
Current liabilities	151.3	136.7	-14.6
Long-term liabilities	74.2	70.9	-3.3
Total Liabilities	225.5	207.6	-17.9
Shareholders' equity	530.4	542.7	+12.2
Noncontrolling interests	2.2	2.1	-0.1
Total net assets	532.6	544.8	+12.2
Total Liabilities and net assets	758.1	752.4	-5.8
Equity ratio	70.0%	72.1%	+2.1%pt

#### **Consolidated Statement of Cash Flow**

(¥bn)

	H1 FY2019 Actual	H1 FY2020 Actual	Y/Y
Operating cash flow	36.5	45.7	+9.3
Investment cash flow	-14.9	-10.0	+4.9
Free cash flow (FCF)	21.5	35.7	+14.2
Financing cash flow	-9.0	-12.0	-3.0
Cash and cash equivalents as of end of period	109.9	209.1	+99.3
Capital expenditure	16.9	8.3	-8.6
Depreciation	12.2	11.5	-0.7

#### **FY2020 Forex Assumptions**

	FY2020	Impact of ¥1 move(full-year, appro *RMB impact of ¥0.1 move	
	H2 Assumptions	Sales	ОР
USD	¥105	¥1.3bn	¥0.1bn
EUR	¥124	¥0.8bn	¥0.4bn
RMB	¥15.2	¥0.7bn	¥0.1bn

<sup>\*</sup> If emerging market currency trends diverge from trends in major currencies contrary to our expectations, it will impact sensitivities

#### OMRON Included in Major ESG Indices (As of October 2020)

#### **ESG Indices which include OMRON**

- DJSI World
- FTSE4Good Index Series
- MSCI ESG Leaders Indexes
- MSCI SRI Indexes
- STOXX Global ESG Leaders indices
- FTSE Blossom Japan Index
- MSCI Japan ESG Select Leaders Index
- MSCI Japan Empowering Women Index 4th consecutive year
- S&P/JPX Carbon Efficient Index

3<sup>rd</sup> consecutive year

5<sup>th</sup> consecutive year

6<sup>th</sup> consecutive year

4<sup>th</sup> consecutive year

5<sup>th</sup> consecutive year

4<sup>th</sup> consecutive year

4<sup>th</sup> consecutive year

3<sup>rd</sup> consecutive year

MEMBER OF **Dow Jones** Sustainability Indices













**2020** CONSTITUENT MSCI JAPAN ESG SELECT LEADERS INDEX



**2020** CONSTITUENT MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)



FY2019 Assessment: Climate Change 'A-', Water Security 'B'



OMRON discloses information and contributes to numerous external surveys for ESG assessment organizations, including the CDP Climate Change & Water Security questionnaires.

#### **External Recognition (As of October 2020)**

#### Domestic ESG awards, selection for inclusion

#### **Japan Association of Corporate Directors**

✓ Corporate Governance of the Year 2018
 METI Minister's Award for Corporate Governance of the Year FY2018



#### **Ministry of the Environment**

✓ FY2018 Minister's Award for Global Warming Prevention Activity

'Implementation of Countermeasures and Dissemination Category' FY2018



#### Sponsored by Nikkei Inc

✓ Nikkei SDGs Management Grand Prix SDGs Strategy/Economic Value Award December 2019

#### Selected by METI, TSE

✓ TSE 2014 Corporate Value Improvement Award, Grand Prix. FY2014



Health & Productivity Stock
2nd consecutive year from FY2018

Health & Productivity: White 500
4th consecutive year from FY2016











#### Selected by Nikkei Inc.

Nikkei 225 March 2019, 1<sup>st</sup> time

#### Down-Top ROIC Tree






#### **Portfolio Management**

#### **Assessing Economic Value**

# Sales Growth B Expecting Growth C Profit Restructuring ROIC(%)

#### **Assessing Competitiveness**



#### **ROIC Definition**

#### <Consol. B/S>

#### LIABILITIES

Current liabilities:

Short-term debt

Notes and accounts payable — trade

Accrued expenses

Income taxes payable

Other current liabilities

Deferred income taxes

Termination and retirement benefits

Other long-term liabilities

Total liabilities

#### NET ASSETS

Shareholders' equity

Common stock

Capital surplus

Legal reserve

Retained earnings

Accumulated other comprehensive

income (loss)

Foreign currency translation adjustments Minimum pension liability adjustments Net unrealized gains on available-for-sale

Net unrealized gains on available-for-sale

securities

Net losses on derivative instruments

Treasury stock

Noncontrolling interests

Total net assets

Total liabilities and net assets



Net income attributable to OMRON shareholders

Invested capital

#### Invested capital\*

= Net assets + Interest-bearing debt

\*The average of previous fiscal year-end result and quarterly results (or forecasts) of current fiscal year.

<u>Capital cost forecast at 6%</u> <u>for FY2017 - 2020</u>

#### **Notes**

- 1. The consolidated statements of OMRON Corporation (the Company) are prepared in accordance with U.S. GAAP.
- Projected results are based on information available to the Company at the time of writing, as well as certain assumptions judged by the Company to be reasonable. Various risks and uncertain factors could cause actual results to differ materially from these projections.
- 3. The presentation slides are based on "Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2021 (U.S. GAAP)." Figures rounded to the nearest million JPY and percentage to one decimal place.

#### Contact:

Investor Relations Department Global Investor & Brand Communications OMRON Corporation

Phone: +81-(0)3-6718-3421

Email: omron-ir@omron.com

Website: www.omron.com